prikaz prve stranice dokumenta B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
  Preuzmi
PDF 2.71 MB
Znanstveni rad - Izvorni znanstveni rad
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Frontiers in Oncology, 12 (2022); 992137. https://doi.org/10.3389/fonc.2022.992137
Infante, Maria Stefania; Salmanton-García, Jon; Fernández-Cruz, Ana; Marchesi, Francesco; Jakšić, Ozren; Weinbergerová, Barbora; Besson, Caroline; Duarte, Rafael F.; Itri, Federico; Valković, Toni; Szotkovski, Tomáš; Busca, Alessandro; Guidetti, Anna; Glenthøj, Andreas; Collins, Graham P.; Bonuomo, Valentina; Sili, Uluhan; Seval, Guldane Cengiz; Machado, Marina; Cordoba, Raul; Blennow, Ola; Abu-Zeinah, Ghaith; Lamure, Sylvain; Kulasekararaj, Austin; Falces-Romero, Iker; Cattaneo, Chiara; Van Doesum, Jaap; Piukovics, Klára; Omrani, Ali S.; Magliano, Gabriele; Ledoux, Marie-Pierre; de Ramon, Cristina; Cabirta, Alba; Verga, Luisa; López-García, Alberto; Da Silva, Maria Gomes; Stojanoski, Zlate; Meers, Stef; Lahmer, Tobias; Martín-Pérez, Sonia; Dávila-Vals, Julio; Van Praet, Jens; Samarkos, Michail; Bilgin, Yavuz M.; Karlsson, Linda Katharina; Batinić, Josip; Nordlander, Anna; Schönlein, Martin; Hoenigl, Martin; Ráčil, Zdeněk; Mladenović, Miloš; Hanakova, Michaela; Zambrotta, Giovanni Paolo Maria; De Jonge, Nick; Adžić-Vukičević, Tatjana; Nunes-Rodrigues, Raquel; Prezioso, Lucia; Navrátil, Milan; Marchetti, Monia; Cuccaro, Annarosa; Calbacho, Maria; Giordano, Antonio; Cornely, Oliver A.; Hernández-Rivas, José-Ángel; Pagano, Livio Više autora...

Citirajte ovaj rad

Infante, M. S., Salmanton García, J., Fernández Cruz, A., Marchesi, F., Jakšić, O., Weinbergerová, B. ... Pagano, L. (2022). B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA). Frontiers in Oncology, 12.. doi: 10.3389/fonc.2022.992137

Infante, Maria Stefania, et al. "B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)." Frontiers in Oncology, vol. 12, 2022. https://doi.org/10.3389/fonc.2022.992137

Infante, Maria Stefania, Jon Salmanton García, Ana Fernández Cruz, Francesco Marchesi, Ozren Jakšić, Barbora Weinbergerová, Caroline Besson, et al. "B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)." Frontiers in Oncology 12 (2022). https://doi.org/10.3389/fonc.2022.992137

Infante, M. S., et al. (2022) 'B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)', Frontiers in Oncology, 12. doi: 10.3389/fonc.2022.992137

Infante MS, Salmanton García J, Fernández Cruz A, Marchesi F, Jakšić O, Weinbergerová B, i sur.. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA). Frontiers in Oncology [Internet]. 10.2022. [pristupljeno 24.12.2024.];12. doi: 10.3389/fonc.2022.992137

M. S. Infante, et al., "B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)", Frontiers in Oncology, vol. 12, Listopad 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:658338. [Citirano: 24.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:658338
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
AutorMaria Stefania Infante
AutorJon Salmanton-García
AutorAna Fernández-Cruz
AutorFrancesco Marchesi
AutorOzren Jakšić
AutorBarbora Weinbergerová
AutorCaroline Besson
AutorRafael F. Duarte
AutorFederico Itri
AutorToni Valković
AutorTomáš Szotkovski
AutorAlessandro Busca
AutorAnna Guidetti
AutorAndreas Glenthøj
AutorGraham P. Collins
AutorValentina Bonuomo
AutorUluhan Sili
AutorGuldane Cengiz Seval
AutorMarina Machado
AutorRaul Cordoba
AutorOla Blennow
AutorGhaith Abu-Zeinah
AutorSylvain Lamure
AutorAustin Kulasekararaj
AutorIker Falces-Romero
AutorChiara Cattaneo
AutorJaap Van Doesum
AutorKlára Piukovics
AutorAli S. Omrani
AutorGabriele Magliano
AutorMarie-Pierre Ledoux
AutorCristina de Ramon
AutorAlba Cabirta
AutorLuisa Verga
AutorAlberto López-García
AutorMaria Gomes Da Silva
AutorZlate Stojanoski
AutorStef Meers
AutorTobias Lahmer
AutorSonia Martín-Pérez
AutorJulio Dávila-Vals
AutorJens Van Praet
AutorMichail Samarkos
AutorYavuz M. Bilgin
AutorLinda Katharina Karlsson
AutorJosip Batinić
AutorAnna Nordlander
AutorMartin Schönlein
AutorMartin Hoenigl
AutorZdeněk Ráčil
AutorMiloš Mladenović
AutorMichaela Hanakova
AutorGiovanni Paolo Maria Zambrotta
AutorNick De Jonge
AutorTatjana Adžić-Vukičević
AutorRaquel Nunes-Rodrigues
AutorLucia Prezioso
AutorMilan Navrátil
AutorMonia Marchetti
AutorAnnarosa Cuccaro
AutorMaria Calbacho
AutorAntonio Giordano
AutorOliver A. Cornely
AutorJosé-Ángel Hernández-Rivas
AutorLivio Pagano
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Onkologija
Sažetak (engleski)
Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFrontiers in Oncology
Brojčani podacivol. 12, 992137
e-ISSN2234-943X
DOIhttps://doi.org/10.3389/fonc.2022.992137
URN:NBNurn:nbn:hr:184:658338
Datum objave publikacije2022-10
URL dokumentahttps://www.frontiersin.org/articles/10.3389/fonc.2022.992137/full
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-11-10 10:34:07